Brief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
18/08/2026 13:56
BRIEF-Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models Akari Therapeutics PLC AKTX.O:
AKARI THERAPEUTICS - AKTX-101 DEMONSTRATES ROBUST ANTI-TUMOR ACTIVITY IN UROTHELIAL CANCER PRECLINICAL MODELS
AKARI THERAPEUTICS - PH1 PAYLOAD SHOWS POTENTIAL TO OVERCOME PAYLOAD-SPECIFIC RESISTANCE
AKARI THERAPEUTICS - CONTINUES TO ADVANCE IND-ENABLING ACTIVITIES FOR AKTX-101 WITH GOAL OF INITIATING PHASE 1 CLINICAL TRIAL IN MID-2027
AKARI THERAPEUTICS - AKTX-101 ACHIEVES STATISTICALLY SIGNIFICANT TUMOR GROWTH INHIBITION IN UROTHELIAL CARCINOMA MODEL
AKARI THERAPEUTICS - DEVELOPING AKTX-102 ADC TARGETING CEACAM5 IN MULTIPLE SOLID TUMORS
Source text: ID:nGNX7FHXTR
Further company coverage: AKTX.O
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics